{"id":26842,"date":"2023-06-27T11:53:00","date_gmt":"2023-06-27T09:53:00","guid":{"rendered":"https:\/\/www.anderapartners.com\/?p=26842"},"modified":"2023-06-27T11:55:11","modified_gmt":"2023-06-27T09:55:11","slug":"allecra-therapeutics-submits-new-drug-application-to-the-u-s-fda-for-exblifep-for-the-treatment-of-complicated-urinary-tract-infections","status":"publish","type":"post","link":"https:\/\/www.anderapartners.com\/en\/allecra-therapeutics-submits-new-drug-application-to-the-u-s-fda-for-exblifep-for-the-treatment-of-complicated-urinary-tract-infections\/","title":{"rendered":"Allecra Therapeutics Submits New Drug Application to the U.S. FDA for EXBLIFEP\u00ae for the Treatment of Complicated Urinary Tract Infections"},"content":{"rendered":"<p><strong> Allecra Therapeutics<\/strong> (\u201cAllecra\u201d) announced today the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for cefepime\/enmetazobactam, an antibiotic combination of the fourth generation cephalosporin cefepime with the proprietary beta lactamase inhibitor, enmetazobactam, for the treatment of complicated urinary tract infections (cUTIs). Upon approval, the antibiotic combination will be marketed under the trademark name, EXBLIFEP\u00ae. EXBLIFEP\u00ae has been designed to combat anti-microbial resistance in gram-negative bacteria, especially resistance mediated by Extended Spectrum Beta Lactamases (or ESBLs). The NDA submission is supported by results from Allecra\u2019s Phase 3 ALLIUM trial, which met criteria for non-inferiority and superiority compared to piperacillin\/tazobactam in the primary composite outcome of clinical cure and microbiological eradication in patients with cUTIs.<\/p>\n<p>&#8220;This filing marks the culmination of a journey that began ten years ago with the formation of Allecra by a syndicate of European venture capital interests. I am extremely proud of and thankful for our small yet dedicated team which has, since company inception, worked diligently to reach this critical milestone,\u201d said<strong> Iain Buchanan, Supervisory Board Member of Allecra Therapeutics<\/strong>.<\/p>\n<p><strong>EXBLIFEP\u00ae<\/strong> was granted Qualified Infectious Disease Product (QIDP) status, which can enable priority review from the FDA and enhanced market exclusivity for applications for medicines that, if approved, would provide critical improvements in the efficiency and safety of antibacterial and antifungal drugs to treat serious or life-threatening infections.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Allecra Therapeutics (\u201cAllecra\u201d) announced today the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for cefepime\/enmetazobactam, an antibiotic combination of the fourth generation cephalosporin cefepime with the proprietary beta lactamase inhibitor, enmetazobactam, for the treatment of complicated urinary tract infections (cUTIs). Upon approval, the antibiotic combination will be&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[123],"class_list":["post-26842","post","type-post","status-publish","format-standard","hentry","category-biodiscovery-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Allecra Therapeutics Submits New Drug Application to the U.S. FDA for EXBLIFEP\u00ae for the Treatment of Complicated Urinary Tract Infections - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/en\/allecra-therapeutics-submits-new-drug-application-to-the-u-s-fda-for-exblifep-for-the-treatment-of-complicated-urinary-tract-infections\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Allecra Therapeutics Submits New Drug Application to the U.S. FDA for EXBLIFEP\u00ae for the Treatment of Complicated Urinary Tract Infections - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"Allecra Therapeutics (\u201cAllecra\u201d) announced today the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for cefepime\/enmetazobactam, an antibiotic combination of the fourth generation cephalosporin cefepime with the proprietary beta lactamase inhibitor, enmetazobactam, for the treatment of complicated urinary tract infections (cUTIs). Upon approval, the antibiotic combination will be...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/en\/allecra-therapeutics-submits-new-drug-application-to-the-u-s-fda-for-exblifep-for-the-treatment-of-complicated-urinary-tract-infections\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-27T09:53:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-27T09:55:11+00:00\" \/>\n<meta name=\"author\" content=\"Nicolas Delsert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Delsert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/allecra-therapeutics-submits-new-drug-application-to-the-u-s-fda-for-exblifep-for-the-treatment-of-complicated-urinary-tract-infections\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/allecra-therapeutics-submits-new-drug-application-to-the-u-s-fda-for-exblifep-for-the-treatment-of-complicated-urinary-tract-infections\/\"},\"author\":{\"name\":\"Nicolas Delsert\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\"},\"headline\":\"Allecra Therapeutics Submits New Drug Application to the U.S. FDA for EXBLIFEP\u00ae for the Treatment of Complicated Urinary Tract Infections\",\"datePublished\":\"2023-06-27T09:53:00+00:00\",\"dateModified\":\"2023-06-27T09:55:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/allecra-therapeutics-submits-new-drug-application-to-the-u-s-fda-for-exblifep-for-the-treatment-of-complicated-urinary-tract-infections\/\"},\"wordCount\":252,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/allecra-therapeutics-submits-new-drug-application-to-the-u-s-fda-for-exblifep-for-the-treatment-of-complicated-urinary-tract-infections\/\",\"url\":\"https:\/\/www.anderapartners.com\/en\/allecra-therapeutics-submits-new-drug-application-to-the-u-s-fda-for-exblifep-for-the-treatment-of-complicated-urinary-tract-infections\/\",\"name\":\"Allecra Therapeutics Submits New Drug Application to the U.S. FDA for EXBLIFEP\u00ae for the Treatment of Complicated Urinary Tract Infections - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"datePublished\":\"2023-06-27T09:53:00+00:00\",\"dateModified\":\"2023-06-27T09:55:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/allecra-therapeutics-submits-new-drug-application-to-the-u-s-fda-for-exblifep-for-the-treatment-of-complicated-urinary-tract-infections\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/en\/allecra-therapeutics-submits-new-drug-application-to-the-u-s-fda-for-exblifep-for-the-treatment-of-complicated-urinary-tract-infections\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/allecra-therapeutics-submits-new-drug-application-to-the-u-s-fda-for-exblifep-for-the-treatment-of-complicated-urinary-tract-infections\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.anderapartners.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Allecra Therapeutics Submits New Drug Application to the U.S. FDA for EXBLIFEP\u00ae for the Treatment of Complicated Urinary Tract Infections\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\",\"name\":\"Nicolas Delsert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"caption\":\"Nicolas Delsert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Allecra Therapeutics Submits New Drug Application to the U.S. FDA for EXBLIFEP\u00ae for the Treatment of Complicated Urinary Tract Infections - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/en\/allecra-therapeutics-submits-new-drug-application-to-the-u-s-fda-for-exblifep-for-the-treatment-of-complicated-urinary-tract-infections\/","og_locale":"en_US","og_type":"article","og_title":"Allecra Therapeutics Submits New Drug Application to the U.S. FDA for EXBLIFEP\u00ae for the Treatment of Complicated Urinary Tract Infections - ANDERA PARTNERS","og_description":"Allecra Therapeutics (\u201cAllecra\u201d) announced today the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for cefepime\/enmetazobactam, an antibiotic combination of the fourth generation cephalosporin cefepime with the proprietary beta lactamase inhibitor, enmetazobactam, for the treatment of complicated urinary tract infections (cUTIs). Upon approval, the antibiotic combination will be...","og_url":"https:\/\/www.anderapartners.com\/en\/allecra-therapeutics-submits-new-drug-application-to-the-u-s-fda-for-exblifep-for-the-treatment-of-complicated-urinary-tract-infections\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2023-06-27T09:53:00+00:00","article_modified_time":"2023-06-27T09:55:11+00:00","author":"Nicolas Delsert","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Nicolas Delsert","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/en\/allecra-therapeutics-submits-new-drug-application-to-the-u-s-fda-for-exblifep-for-the-treatment-of-complicated-urinary-tract-infections\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/en\/allecra-therapeutics-submits-new-drug-application-to-the-u-s-fda-for-exblifep-for-the-treatment-of-complicated-urinary-tract-infections\/"},"author":{"name":"Nicolas Delsert","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c"},"headline":"Allecra Therapeutics Submits New Drug Application to the U.S. FDA for EXBLIFEP\u00ae for the Treatment of Complicated Urinary Tract Infections","datePublished":"2023-06-27T09:53:00+00:00","dateModified":"2023-06-27T09:55:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/en\/allecra-therapeutics-submits-new-drug-application-to-the-u-s-fda-for-exblifep-for-the-treatment-of-complicated-urinary-tract-infections\/"},"wordCount":252,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"articleSection":["andera Life Sciences"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/en\/allecra-therapeutics-submits-new-drug-application-to-the-u-s-fda-for-exblifep-for-the-treatment-of-complicated-urinary-tract-infections\/","url":"https:\/\/www.anderapartners.com\/en\/allecra-therapeutics-submits-new-drug-application-to-the-u-s-fda-for-exblifep-for-the-treatment-of-complicated-urinary-tract-infections\/","name":"Allecra Therapeutics Submits New Drug Application to the U.S. FDA for EXBLIFEP\u00ae for the Treatment of Complicated Urinary Tract Infections - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"datePublished":"2023-06-27T09:53:00+00:00","dateModified":"2023-06-27T09:55:11+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/en\/allecra-therapeutics-submits-new-drug-application-to-the-u-s-fda-for-exblifep-for-the-treatment-of-complicated-urinary-tract-infections\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/en\/allecra-therapeutics-submits-new-drug-application-to-the-u-s-fda-for-exblifep-for-the-treatment-of-complicated-urinary-tract-infections\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/en\/allecra-therapeutics-submits-new-drug-application-to-the-u-s-fda-for-exblifep-for-the-treatment-of-complicated-urinary-tract-infections\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.anderapartners.com\/en\/"},{"@type":"ListItem","position":2,"name":"Allecra Therapeutics Submits New Drug Application to the U.S. FDA for EXBLIFEP\u00ae for the Treatment of Complicated Urinary Tract Infections"}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c","name":"Nicolas Delsert","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","caption":"Nicolas Delsert"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/26842","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/comments?post=26842"}],"version-history":[{"count":0,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/26842\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/media?parent=26842"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/categories?post=26842"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}